KR20130083090A

KR20130083090A - Anti-egfr of cancer cell antibodies and uses thereof

Info

Publication number: KR20130083090A
Application number: KR1020120003065A
Authority: KR
Inventors: 차상훈
Original assignee: 강원대학교산학협력단
Priority date: 2012-01-10
Filing date: 2012-01-10
Publication date: 2013-07-22

Abstract

PURPOSE: A binding molecule which specifically binds to epidermal growth factor receptor (EGFR) in cancer cells is provided to diagnose and treat cancer. CONSTITUTION: An antibody which specifically binds to cancer cells comprises : a light chain complementary determining region 1 (CDR1) region of L (24)-L (25)-L (26)-L (27)-L (27A)-L (28)-L (29)-L (30)-L (31)-L (32)-L (33)-L (34); a light chain CDR2 region of L (50)-L (51)-L (52)-L (53)-L (54)-L (55); a light chain CDR3 region of L (89)-L (90)-L (91)-L (92)-L (93)-L (94)-L (95)-L (95A)-L (96)-L (97); a heavy chain CDR1 region of H (31)-H (32)-H (33)-H (34)-H (35); a heavy chain CDR2 region of H (50)-H (51)-H (52)-H (52A)-H (53)-H (54)-H (55)-H (56)-H (57)-H (58)-H (59)-H (60)-H (61)-H (62)-H (63)-H (64)-H (65); and a heavy chain CDR3 region of H (95)-H (96)-H (97)-H (98)-H (99)-H (100)-H (100A)-H (101)-H (102). The residues are numbered according to Kabat numbering system.

Description

Anti-EGFR of cancer cell antibodies and uses thereof

The present invention relates to binding molecules that specifically bind to EGFR of cancer cells and their use.

Colorectal cancer is one of the most common cancers in the world, and 50% of people in their 70s develop colorectal cancer and about 1 in 10 people develop malignant tumors. These results vary by nationality but are the second highest cancer-related mortality in the West, and the first among smokers (Parker et al., 1996).

One of the factors associated with this major cancer-related death disease may be called EGFR. The growth and development of cancer cells can be caused by a variety of causes, but it is typical to alter the specific signaling system resulting from genetic changes that regulate cell survival, proliferation, mobility, and differentiation, and thus the basic mechanism of immortalization. Accompanying (Huang Sm., Et al 1999). In particular, EGFR, which is one of the ErbB family receptors, is also called ErbB1, which means breast, gastric, ovarian, non-small cell lung cancer, head and neck cancer, It is known to cause immortalization in solid cancers including prostate cancer (DS Salomon et al., 1995).

As such, EGFR is a potent prognostic factor for solid cancers. Increased expression of EGFR has been linked to decreased overall survival rate (OS) or recurrence-free survival (RFS). In addition, 70% of studies related to cervical cancer, bladder cancer, and esophageal cancer, and 52% of studies related to pancreatic cancer, breast cancer, endometrium, pancreas, and stomach cancer reported decreased OS and RFS due to increased EGFR expression. (R.I. Nicholson., Et al 2001) (Table. 1.).

The first FDA approved (2004) therapeutic EGFR-targeted monoclonal antibody is Cetuximab and is still the most widely used to date. The approved field of treatment is Metastatic colorectal cancer (CRC), and non-small-cell lung carcinoma (NSCLC) is in clinical trial 3 (Pirker R. et al., 2009). Cetuximab is a chimeric monoclonal antibody with affinity (10 ^-10 ), which is more affinity than naturally occurring EGF, using IgG1 in Ig format. It inhibits the binding of EGF, vascular endotherial growth factor (VEGF) and IL-8, and inhibits Ras / Raf / MAP, AKT and JAK / STAT pathways. This causes an increase in cell death by stopping the G1 phase of the cell cycle (M. Ng, D. Cunningham et al., 2004).

Next, the FDA and EMEA approved antibodies were Panitumumab, which was composed of fully human antibodies with XenoMouse as a template unlike Cetuximab (MJ Mendez 1997. CRC and Head and neck squamous cell carcinoma (HNSCC) caused by K-ras). (O'bryne KJ et al 2009), however, as with Cetuximab, 90% of patients developed side effects of skin rash when they were actually administered to patients and needed further treatment (Van Cutsem). et al., 2007).

In contrast, Nimotuzumab, developed as an anti-EGFR antibody that significantly reduces skin rash, was approved by EMEA in 2008. Nimotuzumab has an affinity of 10 ^-8 . Notably, the antibody had no oscillating side effects in animal studies such as Cercopithecus aethiops sabaeus (Green Monkeys) (Arteaga et al., 2007). It is believed that this side effect less than the two approved antibodies mentioned above is due to relatively 10-100 times less antigen-antibody affinity (Tikhomirov I, et al., 2009). This is because EGFR is not overexpressed in normal cells, resulting in less binding to normal cells compared to cancer cells, and low affinity and thus no unwanted toxicity (Garrido G et al., 2009). Nimotuzumab has lower side effects than other therapeutic agents, but is known as a humanized antibody of mouse origin (Mateo C et al., 1997) (Table. 3.).

An object of the present invention is to provide a binding molecule that specifically binds to EGFR of cancer cells produced from human cells.

It is another object of the present invention to provide an antibody-drug conjugate in which a drug for treating cancer cells is bound to a binding molecule that specifically binds to EGFR of cancer cells.

It is another object of the present invention to provide a pharmaceutical composition for treating cancer.

The present invention is based on the Kabat numbering system, L (24) -L (25) -L (26) -L (27) -L (27A) -L (28) -L (29) -L ( Light chain CDR1 region represented by 30) -L (31) -L (32) -L (33) -L (34); Light chain CDR2 region represented by L (50) -L (51) -L (52) -L (53) -L (54) -L (55);

L (89) -L (90) -L (91) -L (92) -L (93) -L (94) -L (95) -L (95A) -L (96) -L (97) Indicated light chain CDR3 regions; A heavy chain CDR1 region represented by H (31) -H (32) -H (33) -H (34) -H (35); H (50) -H (51) -H (52) -H (52A) -H (53) -H (54) -H (55) -H (56) -H (57) -H (58)- A heavy chain CDR2 region represented by H (59) -H (60) -H (61) -H (62) -H (63) -H (64) -H (65); And heavy chain CDR3 represented by H (95) -H (96) -H (97) -H (98) -H (99) -H (100) -H (100A) -H (101) -H (102). Includes an area,

L 24 is R;

L 25 is A;

L 26 is S;

L 27 is Q or E;

L 27A is T;

L 28 may be any one of S, V or N;

L 29 is I or S;

L 30 is any one of S, G or V;

L 31 is R or S;

L 32 is any one of Y, Q, W or S;

L 33 is L or N;

L 34 is any one of N, A or L;

L 50 is G or A;

L 51 is A;

L 52 is S;

L 53 is any one of R, S, N or T;

L 54 is L or R;

L 55 may be any one of E, A, R or Q;

L 89 is Q;

L 90 is Q;

L 91 is any one of S, Y or A;

L 92 is any one of D, G, T, N or Y;

L 93 is any one of S, I or N;

L 94 is any one of V, S, F, W or T;

L 95 is P;

L 95A is P;

L 96 is any one of V, R, L or Y;

L 97 is T;

H (31) is any one of N, D or S;

H (32) is Y

H 33 is any one of N, W, A or G;

H 34 is any one of I, M or V;

H 35 is any one of N, T, H or S;

H 50 is any of W, N or G;

H 51 is M or I;

H 52 is any one of N, R, S or I;

H 52A is any one of P, Q or W;

H 53 is any one of Y, D, N or V;

H 54 is any one of T, G, N or F;

H 55 is any one of G, N or A;

H 56 is any one of D, E, S, N or T;

H 57 is any one of T, K, V or P;

H 58 is any one of G, Y, V, D or N;

H 59 is Y;

H 60 is A or L;

H 61 is Q or D;

H 62 is any one of K, S or N;

H 63 is F or V;

H 64 is any of Q, K or R;

H 65 is G;

H 95 is any one of R, E, D or Y;

H 96 is any one of W, Y, D or R;

H (97) is any one of D, E, G or Y;

H 98 is any one of N, Y, A or F;

H (99) is any one of F, Y, T or D;

H (100) is any one of G, D or W;

H (100A) is any one of A, I, M, W or L;

H 101 is D; And

H 102 relates to an antibody that specifically binds to cancer cells, which is one of I, Y, V or P. According to an embodiment of the present invention, the light chain CDR 1 is any one of SEQ ID NOs: 1 to 5; The light chain CDR 2 is any one of SEQ ID NOs: 6 to 10; The light chain CDR 3 is any one of SEQ ID NOs: 11 to 15; The heavy chain CDR 1 is any one of SEQ ID NOs: 16 to 20; The heavy chain CDR 2 is any one of SEQ ID NOs: 21 to 25; And the heavy chain CDR 3 is any one of SEQ ID NOs: 26 to 30, and according to one embodiment of the present invention, the antibody comprises an amino acid sequence of any one group selected from the following group: The light chain CDR 1 region represented by SEQ ID NO: 1, the light chain CDR 2 region represented by SEQ ID NO: 6, the light chain CDR 3 region represented by SEQ ID NO: 11, the heavy chain CDR 1 region represented by SEQ ID NO: 16, represented by SEQ ID NO: 21 A heavy chain CDR 2 region and a heavy chain CDR 3 region represented by SEQ ID NO: 26; The second group includes the light chain CDR 1 region represented by SEQ ID NO: 2, the light chain CDR 2 region represented by SEQ ID NO: 7, the light chain CDR 3 region represented by SEQ ID NO: 12, the heavy chain CDR 1 region represented by SEQ ID NO: 17, SEQ ID NO: A heavy chain CDR 2 region represented by 22 and a heavy chain CDR 3 region represented by SEQ ID NO: 27; The third group includes a light chain CDR 1 region represented by SEQ ID NO: 3, a light chain CDR 2 region represented by SEQ ID NO: 8, a light chain CDR 3 region represented by SEQ ID NO: 13, a heavy chain CDR 1 region represented by SEQ ID NO: 18, SEQ ID NO: A heavy chain CDR 2 region represented by 23 and a heavy chain CDR 3 region represented by SEQ ID NO: 28; The fourth group includes the light chain CDR 1 region represented by SEQ ID NO: 4, the light chain CDR 2 region represented by SEQ ID NO: 9, the light chain CDR 3 region represented by SEQ ID NO: 14, the heavy chain CDR 1 region represented by SEQ ID NO: 19, SEQ ID NO: A heavy chain CDR 2 region represented by 24 and a heavy chain CDR 3 region represented by SEQ ID NO: 29; And the fifth group includes a light chain CDR 1 region represented by SEQ ID NO: 5, a light chain CDR 2 region represented by SEQ ID NO: 10, a light chain CDR 3 region represented by SEQ ID NO: 15, a heavy chain CDR 1 region represented by SEQ ID NO: 20, a sequence A heavy chain CDR 2 region represented by Number 25 and a heavy chain CDR 3 region represented by SEQ ID NO: 30; According to one embodiment of the invention, the antibody comprises the amino acid sequence of the second group or the third group, according to an embodiment of the present invention, the antibody is any one of SEQ ID NO: 31 to SEQ ID NO: 35 one; And an amino acid sequence of any one of SEQ ID NOs: 36 to 40, and according to one embodiment of the present invention, the antibody is specific for a cancer cell comprising an amino acid sequence of any one group selected from the following groups Antibody bound to SEQ ID NO: 6 and SEQ ID NO: 31 and SEQ ID NO: 36; The seventh group comprises SEQ ID NO: 32 and SEQ ID NO: 37; The eighth group comprises SEQ ID NO: 33 and SEQ ID NO: 38; The ninth group comprises SEQ ID NO: 34 and SEQ ID NO: 39; And Group 10 includes SEQ ID NO: 35 and SEQ ID NO: 40; According to one embodiment of the invention, the antibody comprises an amino acid sequence of the seventh or eighth group, in accordance with an embodiment of the present invention, the antibody is EGFR (Epidermal growth factor receptor) of cancer cells Specifically bind.

According to an embodiment of the present invention according to the Kabat numbering system (Kabat numbering system), L (24) -L (25) -L (26) -L (27) -L (27A) -L (28) -L ( 29) -L (30) -L (31) -L (32) -L (33) -L (34); A second area represented by L (50) -L (51) -L (52) -L (53) -L (54) -L (55); L (89) -L (90) -L (91) -L (92) -L (93) -L (94) -L (95) -L (95A) -L (96) -L (97) A third area displayed; A fourth region represented by H (31) -H (32) -H (33) -H (34) -H (35); H (50) -H (51) -H (52) -H (52A) -H (53) -H (54) -H (55) -H (56) -H (57) -H (58)- A fifth region represented by H (59) -H (60) -H (61) -H (62) -H (63) -H (64) -H (65); And a sixth represented by H (95) -H (96) -H (97) -H (98) -H (99) -H (100) -H (100A) -H (101) -H (102). Includes an area,

L 24 is R;

L 25 is A;

L 26 is S;

L 27 is Q or E;

L 27A is T;

L 28 may be any one of S, V or N;

L (29) is I or S

L 30 is any one of S, G or V;

L 31 is R or S;

L 32 is any one of Y, Q, W or S;

L 33 is L or N;

L 34 is any one of N, A or L;

L 50 is G or A;

L 51 is A;

L 52 is S;

L 53 is any one of R, S, N or T;

L 54 is L or R;

L 55 may be any one of E, A, R or Q;

L 89 is Q;

L 90 is Q;

L 91 is any one of S, Y or A;

L 92 is any one of D, G, T, N or Y;

L 93 is any one of S, I or N;

L 94 is any one of V, S, F, W or T;

L 95 is P;

L 95A is P;

L 96 is any one of V, R, L or Y;

L 97 is T;

H (31) is any one of N, D or S;

H (32) is Y

H 33 is any one of N, W, A or G;

H 34 is any one of I, M or V;

H 35 is any one of N, T, H or S;

H 50 is any of W, N or G;

H 51 is M or I;

H 52 is any one of N, R, S or I;

H 52A is any one of P, Q or W;

H 53 is any one of Y, D, N or V;

H 54 is any one of T, G, N or F;

H 55 is any one of G, N or A;

H 56 is any one of D, E, S, N or T;

H 57 is any one of T, K, V or P;

H 58 is any one of G, Y, V, D or N;

H 59 is Y;

H 60 is A or L;

H 61 is Q or D;

H 62 is any one of K, S or N;

H 63 is F or V;

H 64 is any of Q, K or R;

H 65 is G;

H 95 is any one of R, E, D or Y;

H 96 is any one of W, Y, D or R;

H (97) is any one of D, E, G or Y;

H 98 is any one of N, Y, A or F;

H (99) is any one of F, Y, T or D;

H (100) is any one of G, D or W;

H (100A) is any one of A, I, M, W or L;

H 101 is D; And

H 102 provides a binding molecule that is any one of I, Y, V or P. In one embodiment of the present invention, the first region is any one of SEQ ID NOs: 1 to 5; The second region is any one of SEQ ID NOs: 6-10; The third region is any one of SEQ ID NOs: 11 to 15; The fourth region is any one of SEQ ID NOs: 16-20; The fifth region is any one of SEQ ID NOs: 21 to 25; And the sixth region is any one of SEQ ID NOs: 26 to 30, and in one embodiment of the present invention, the antibody comprises an amino acid sequence of any one group selected from the following group: A first region represented by number 1, a second region represented by SEQ ID NO: 6, a third region represented by SEQ ID NO: 11, a fourth region represented by SEQ ID NO: 16, a fifth region represented by SEQ ID NO: 21, and a sequence A sixth area indicated by the number 26; The second group includes a first region represented by SEQ ID NO: 2, a second region represented by SEQ ID NO: 7, a third region represented by SEQ ID NO: 12, a fourth region represented by SEQ ID NO: 17, and represented by SEQ ID NO: 22. A sixth region represented by a fifth region and SEQ ID NO: 27; The third group includes a first region represented by SEQ ID NO: 3, a second region represented by SEQ ID NO: 8, a third region represented by SEQ ID NO: 13, a fourth region represented by SEQ ID NO: 18, and represented by SEQ ID NO: 23. A sixth region represented by a fifth region and SEQ ID NO: 28; The fourth group includes a first region represented by SEQ ID NO: 4, a second region represented by SEQ ID NO: 9, a third region represented by SEQ ID NO: 14, a fourth region represented by SEQ ID NO: 19, and represented by SEQ ID NO: 24. A fifth region and a sixth region represented by SEQ ID NO: 29; And the fifth group is represented by SEQ ID NO: 25, a first region represented by SEQ ID NO: 5, a second region represented by SEQ ID NO: 10, a third region represented by SEQ ID NO: 15, a fourth region represented by SEQ ID NO: 20, and SEQ ID NO: 25 And a sixth region represented by SEQ ID NO: 30, wherein in one embodiment of the present invention, the binding molecule comprises a second or third group of amino acid sequences, and in one embodiment of the present invention, the binding The molecule is any one of a single-chain variable fragment (scFv), a disulfide-stabilized Fv antibody fragment (DsFv), or a bispecific antibody.

According to an embodiment of the present invention, an antibody-drug conjugate (ADC) in which a drug is bound to the antibody of any one of claims 1 to 8 is provided.

According to an embodiment of the present invention, a vector comprising a gene encoding the antibody is provided.

According to an embodiment of the present invention, a cell line comprising the vector is provided, and according to an embodiment of the present invention, the cell line is any one of A. TG1, ER2537, or Electro ten-blue.

According to one embodiment of the invention, there is provided a method for producing an antibody comprising the step of transfecting the vector into a cell line, according to one embodiment of the invention, the cell line is A. TG1, ER2537 or Electro Any one of ten-blue, according to one embodiment of the present invention, the antibody specifically binds to cancer cells, and according to one embodiment of the present invention, the antibody specifically binds to EGFR of cancer cells.

According to an embodiment of the present invention, there is provided a pharmaceutical composition for treating cancer comprising the antibody or the antibody-drug conjugate (ADC) of claim 9, and according to an embodiment of the present invention, the composition is an oral dosage form. , External preparations, suppositories or sterile injectable solutions.

According to an embodiment of the present invention, there is provided a kit for diagnosing cancer comprising the antibody.

According to one embodiment of the invention, there is provided a method for providing information on the presence of EGFR protein in cancer cells comprising the step of reacting the antibody with the desired sample.

According to an embodiment of the present invention, there is provided a method for treating cancer, comprising administering to a mammal a composition for treating cancer comprising the antibody or the antibody-drug conjugate (ADC).

As used herein, a binding molecule refers to an intact immunoglobulin comprising a monoclonal antibody, such as a chimeric, humanized or human monoclonal antibody, or an immunoglobulin that binds to an antigen. Regardless of the structure, the antigen-binding fragment binds to the same antigen recognized by intact immunoglobulins. "Antigen-binding fragments" in particular Fab, F (ab '), F (ab') ₂ , Fv, dAb, Fd, complementarity determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single -Chain antibodies, single-chain phage antibodies, diabodies, triabodies, tetrabodies, polypeptides containing one or more fragments of immunoglobulin sufficient to bind a particular antigen to the polypeptide, and the like. The fragments may be produced synthetically or by enzymatic or chemical digestion of complete immunoglobulins or may be produced genetically by recombinant DNA techniques. Production methods are well known in the art.

The compositions comprising the substances according to the invention can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories or sterile injectable solutions, respectively, according to conventional methods. Can be. More specifically, when formulating the composition, it can be prepared using a diluent or an excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, syrups and the like, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used diluents such as water and liquid paraffin . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

Compounds of the invention, in particular binding molecules of the invention, are particularly useful as diagnostic reagents in detecting cancer cells.

Preferably, the compounds of the present invention used in the diagnostic composition are detectably labeled. Various methods that can be used to label biomolecules are well known to those skilled in the art and are contemplated within the scope of the present invention. These methods are described in Tijssen, 'Practice and theory of enzyme immunoassays', Burden, RH and von Knippenburg (Eds), Volume 15 (1985), 'Basic methods in molecular biology'; Davis LG, Dibmer MD; Acad. Press, London (1987), or in the series 'Methods in Enzymology', Academic Press, Inc .; Battey Elsevier (1990), Mayer et al., (Eds.) Immunochemical methods in cell and molecular biology.

There are many other markings and marking methods known to those skilled in the art. Examples of marking classes that can be used in the present invention include enzymes, radioactive isotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds and bioluminescent compounds.

Commonly used markers include fluorescent substances (e.g., fluorescein, rhodamine, Texas red, etc.), enzymes (such as horseradish peroxidase,? -Galactosidase, alkaline phosphatase), radioactive isotopes 32 P or 125 I), biotin, digoxigenin, colloidal metals, chemiluminescent or bioluminescent compounds (such as dioxetane, luminol or acridinium). Methods of labeling enzymes or biotinyl groups such as covalent bonding, iodination, phosphorylation, biotinylation, and the like are well known in the art.

Detection methods include, but are not limited to, autoradiography, fluorescence microscopy, direct and indirect enzyme reactions, and the like. Commonly used detection assays include radioisotopes or non-radioisotope methods. These include Western blotting, overlay-analysis, Radioimmuno Assay (RIA) and Immune Radioimmunometric Assay (IRMA), Enzyme Immuno Assay (EIA), Enzyme Linked Immuno Sorbent Assay (ELISA), Fluorescent Immuno Assay (CIA) and Chemiluminoluminescent Immune Assay).

The antibody according to the present invention can be used in the form of a drug-conjugated antibody-drug conjugate. When an antibody-drug conjugate (ADC), that is, an immunoconjugate, is used for local delivery of a drug, the drug moiety can be targeted to the infected cells. If the drug is administered without conjugation, This can lead to unacceptable levels of toxicity. By increasing the selectivity of polyclonal and monoclonal antibodies (mAbs) as well as drug-linking and drug-releasing properties, the maximum efficacy and minimal toxicity of the ADC can be improved.

Conventional means of attaching the drug moiety to the antibody, ie, via covalent linkage, generally results in a heterogeneous molecular mixture in which the drug moiety is attached to numerous sites on the antibody. For example, cytotoxic drugs can typically be conjugated with an antibody, often through numerous lysine residues of the antibody, to produce a heterogeneous antibody-drug conjugate mixture. Depending on the reaction conditions, such heterogeneous mixtures typically have an antibody distribution between 0 and about 8 or more attached to the drug moiety. In addition, each aliquot of the conjugate with a specific integer ratio drug moiety-to-antibody is a potentially heterogeneous mixture in which the drug moiety is attached to various sites on the antibody. Antibodies are large, complex, structurally diverse biomolecules, and often have many reactive functional groups. Reactivity with linker reagents and drug-linker intermediates depends on factors such as pH, concentration, salt concentration and cosolvent.

Through the antibody, antibody-drug conjugate, and diagnostic method specifically binding to EGFR of cancer cells according to the present invention, it is possible to diagnose the occurrence of cancer, it can be used as a method for treating cancer.

1 is a result of performing ELISA to determine the antigen binding specificity of the human anti-EGFR Fab molecule according to an embodiment of the present invention.
2 is a flow cytometry analysis (FCA) result for measuring the binding force of Fab antibody to naïve EGFR according to an embodiment of the present invention.
Figure 3 is a photograph showing the internalization of the anti-EGFR Fab antibody to A431 cells according to an embodiment of the present invention.
Figure 4 shows the results of ELISA to determine the human or murine EGFR specificity of the anti-EGFR Fab molecule according to an embodiment of the present invention.
Figure 5 is a table (A) and graph (B) showing the inhibitory effect of EG L2, L3, L4, L5 and L6 on ligand-induced EGFR phosphorylation according to an embodiment of the present invention.
6 is a result of performing Surface Plasmon resonance (SPR) to measure the binding force of EG L2, L3, L4, L5 and L6 according to an embodiment of the present invention. 6a: Cetuximab-Fab, 6b: Panitumumab-Fab, 6c: EG L2, 6d: EG L3, 6e: EG L4, 6f: EG L5, 6g: EG L6.
Figure 7 is the result of performing the SPR to compare the EGFR binding position of Fab and Cetuximab-Fab according to an embodiment of the present invention. 7a EG L2, 7b: EG L3, 7c: EG L4, 7d: EG L5, 7e: EG L6

Hereinafter, the components and technical features of the present invention will be described in more detail with reference to the following examples. However, the following examples are intended to illustrate the contents of the present invention and are not intended to limit the scope of the invention.

Example 1. Preparation of Antibody Library

1.1 Cloning

All DNA cloning methods were performed with standard methods already reported (Sambrook et al., 1989). Pfu or Ex- Tag DNA polymerase and all restriction enzymes used for PCR were purchased from Takara (Japan). Cloning and phage production and Fab antibody expression hosts include TG1 [ supE thi-1? (Lac-proAB)? (MrcB-hsdSM) 5 (rK- mK-) [F'traD36 proAB lacIq lacZ? M15] (Amersham Pharmacia Biotech, Sweden).

1.2 Cell Culture

Human epithelial carcinoma A431, human prostate cancer DU145, hepatocarcinoma HepG2 selected as EGFR negative cell line as EGFR expressing cell line, fibroblast NIH3T3 cell line Was purchased from the Korea Cell Line Bank (KCLB, Korea). DMEM (invitrogen, USA), 10% Hyclone fetal bovine serum (FBS) (Thermo Fisher Scientific, MA, USA), penicillin 100 units / ml, streptomycin (Invitrogen, USA) in a composition of 100 ug / ml 37? Cultured in a CO ₂ incubator.

1.3 Panning HuDVDFAb-8L Antibody Library

Phage antibodies were prepared from Ex12 helper phage (IG Therpay Co., Korea) and HuDVFab-8L (IG Therapy Co., Korea) libraries (Hur et al., 2010), and phage antibodies attached to A431 cells were identified as' Biopanning and Rapid Analysis of selective Interactive Ligands (BRASIL) 'method was obtained by modifying (Giordano et al., 2001).

Total 10 ¹² cfu phage antibodies were reacted with 1 ml of DMEM containing 1% bovine serum albumin (BSA) (Sigma-Aldrich, USA). After 4 hours and 2 hours of reaction in a stirrer, A431 cells were washed with DMEM containing 1% BSA, and 400 μl of cells bound with phage were prepared in an organic solvent layer (dibutyl phthalate: cyclohexane). = 9: 1 [v / v]). After centrifugation at 10,000 rpm for 4 minutes at 4 ° C, the tube containing the precipitated cells was placed in liquid nitrogen and rapidly frozen, and then the bottom of the tube was removed using a microcentrifuge tube cutter (GeneMate). Cut.

The obtained cells were resuspended in 100 [mu] l of PBS, and then infected at 37 [deg.] C. in order to infect TG1 light chain host E.Coli (TG-L1 to TG-L8) cells in which the light chain was fixed. After incubation for 2 hours YT / ACT (2x YT medium with 50ug / ml Empicillin, 10ug / ml Carbenicilin, 10ug / ml Tetracycline) agar plate was plated at 37 ℃ overnight.

To amplify colonies containing DNA with specific binding capacity with EX-12 helper phage, scraping was carried out through 40 ml of 2x YT / G (culture medium containing 2x YT glucose) medium and 2 ml of OD Cells with ₆₀₀ = 0.5 were infected at 37 ° C. with the addition of EX-12 helper phage. Only cells infected with phage were obtained by centrifugation and contained 2x YT / ACTKA (2x YT empicillin 50ug / ml, carbenicillin 10ug / ml, tetracycline 10ug / ml, kanamycin 50ug / ml and arabinose 0.001%. Resuspended) and incubated overnight at 27 ℃.

In this manner, a total of four cell pannings were performed. Since then, traditional biopanning has been applied (Song et al ., 2009). Recombinant human EGFR-Fc protein (R & D systems, USA) was diluted in coating buffer (0.1M NaHCO ₃ , pH9.6) and attached to an Immun Tube (Nunc, Denmark) followed by PBS ( A 3% milk solution diluted in phosphate-buffered saline was used for the block. Phage-antibody conjugates derived from cell panning were inoculated in immuno tubes and incubated at 4 ° C. for 2 hours.

1.4 Enzyme-linked immunosorbent assay (ELISA)

All recombinant protein antibodies used in this experiment were purchased from the R & D system except for BSA and maltose binding protein (MBP-IL-15) (IG Therapy Co.).

ELISA was coated overnight at 4 ° C. by diluting EGFR-Fc, sEGFR, Her-2-Fc, c-Met, BSA, MBP-IL-15 to 10 ug / ml in coating buffer (0.1 M NaHCO ₃ , pH9.6). It was. In order to prevent nonspecific binding, the 3% milk powder solution diluted in PBS was reacted at 37 ° C for 1 hour, and then soluble Fab molecules were inoculated into each well and reacted at 37 ° C for 1 hour. Anti-human kappa L chain pAb (Sigma-Aldrich) conjugated to horseradish peroxidase (HRPO) was used at a dilution of 1: 3000 to analyze the antibody bound to the antigen. The substrate used was TMB (3,3'5,5'-tetramethyl bezidine) (Sigma-Aldrich) and the absorbance was measured on a 450 nm ELISA reader (Biorad, USA).

1.5 Flow cytometry analysis

FACS were all performed at 4 ° C. In order to analyze Fab molecules bound to cells, A431 and DU145 cells were used as positive cell lines at about ⁵ × 10 ⁵ cell / tube, and HepG2 and NIH3T3 were used as negative cell lines. The cells were washed with wash buffer containing 2% FBS, 1% NaN ₃ in PBS (137mM NaCL, 3mM KCl, 8mM Na ₂ HPO ₄ , 1mM KH ₂ PO ₄ , Ph7.3) , Cetuximab and soluble Fabs (EG L2 ~ L6) were bound for 40 minutes. After washing three times, FBS (Fluorescein isothiocyanate) (Sigma-Aldrich) conjugated with goat anti-κL light chain pAb was diluted in PBSB (PBS containing 2% EBS) for 30 minutes. After washing three times with PBSB, FACScan (Becton Dickinson, USA) was used to measure the cells bound to the antibody.

1.6 E.Coli Fermentation and Fab Purification

The host E. coli used TG1 for Fab production including VH-CH and VL-CL. Inoculate the cells in 25ml 2x YT / ACT medium for spawn culture and incubate overnight at 27 ° C, then re-inoculate 2.5L 2x YT / ACT with 1% antifoam in log phase. Incubated until. By incubating the cultured cells with 0.02% arabinose and 0.1 mM IPTG for 15 hours at 27 ° C, the water-soluble Fab antibodies were expressed.

The supernatant was obtained by centrifugation at 6500 rpm for 10 minutes, and then only insoluble protein was precipitated using ammonium sulfate precipitation. Centrifugation was performed at 13000 rpm for 30 minutes, and only precipitated insoluble protein was collected and resuspended in PBS. 5 ml of CNBr-activated sepharose (Pharmacia) was added to the suspension, followed by shaking for 1 hour at 4 ° C. to allow anti-human IgG (Fab) '2 and Fab antibodies to bind.

Centrifugation was performed at 1000 rpm for 5 minutes to remove other proteins that could not bind anti-human IgG (Fab) '2. The obtained CNBr-activated sepharose beads were washed in a Bunchner funnel (Pharmacia), followed by washing with 50 ml of PBS. To remove Fab binding from CNBr-activated sepharose, 0.2M Glycine-HCl, 5 ml of pH2.9 was used as extraction buffer. The extracted solution was neutralized with Tris-HCl (pH 9.0) to prevent denaturation of Fab structure with pH.

1.7 Immunofluorescence assay

Immunofluorescence was used to verify whether anti-EGFR human Fabs are attached to naïve EGFR to form dimers and cause internalization. A431 was used as the EGFR positive cell line and NIH3T3 was used as the EGFR negative cell line. These cells were inoculated in 24 well cell culture dishes (SPL, Korea) with coverslips at 5 x 10 ⁴ / well, respectively, and incubated for 12 hours to acclimate to the cover glass surface.

Fab antibodies were inoculated at a concentration of 10 ug / ml and incubated at 5% CO ₂ , 37 ° C. for about 3 hours. In order to remove the Fab bound to the EGFR remaining on the cell surface was washed three times with stripping buffer consisting of 50 mM glycine (pH2.8), 500mM NaCl. In order to fix the cells, 4% paraformaldehyde was prepared in PBS and reacted for 10 minutes at room temperature. After washing three times with PBS, -20 ° C acetone was added for 30 seconds to induce the generation of pores on the cell surface. PBS-2% FBS was used as a blocker to prevent nonspecific binding after three rewashes with PBS. In order to detect Fab antibodies inserted into cells via internalization, Fluorescein isothiocyanate (Sigma-Aldrich) conjugated with goat anti-κL pAb was added and analyzed by Olympus LX70 FV300 confocal microscope (Japan) 488 nM Laser. .

1.8 Phosphotyrosine inhibition assay

It was confirmed that EG L2 to L6 Fab antibodies bound to EGFR can inhibit tyrosine phosphorylation, which is one of the signal transductions that occur in actual cells. The cell line of interest was A431 and Cetuximab-Fab and Panitumumab-Fab as positive antibodies and anti-IL15 as negative antibodies were used.

A431 was dispensed at 1 × 10 ⁵ cells / well into 24well cell culture plates (SPL, Korea) and adapted for 12 hours. Incubated for 24 hours in the EBS-excluded body to be a Serum starved condition. 20 nm EGF (Epidermal Growth Factor) (R & D system) was added to each well, and Fab antibodies were added at 10 nM and 40 nM at the same time and reacted at 37 ° C. for 5 minutes at 5% CO ₂ . After washing twice with PBS, RIW buffer solution (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 2ug / ml leupeptin, 2ug / ml) was added to each well. Aprotinin (1mM Na ₃ VO ₄ , 1mM PMSF) 100ul was added to react for 10 minutes at room temperature to induce cell lysis.

Lysates were obtained and centrifuged to remove unlyzed cells, and only the supernatant was taken and protein quantified with Bradford (Biorad) solution. The prepared 10% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel) was loaded into the well at a concentration of 400 ug / ml and electrophoresed, and transferred to a nitrocellulose membrane for 15 volts for 7 minutes through an iBlot gel transfer system (Invitrogen). I was. Blocking the nitrofiber membranes with PBS-3% BSA followed by addition of mouse anti-phophotyrosine (Millipore) or mouse anti-Actin (Millipore). Goat anti-mouse Fc Alkaline phoaphatase (Sigma-aldrich) was then added, and NBT / BCIP (Duchefa) was used as a substrate to observe the blot signal.

1.9 Surface plasmon resonance (SPR)

Surface plasmon resonance experiments were performed to determine the affinity and epitope differences between Cetuximab-Fab, Panitumumab-Fab, and EG L2 to L6 Fab. The instrument used was a Biacore X biosensor (Biacore AB, Sweden) and 400 RU of EGFR-Fc (R & D system) antigen was added to the carboxyl methylated dextran of Fc2 from the CM5 sensor chip (GE Healthcare Bio-sciences AB, Sweden). immobilized to a value of (response units). BSA was immobilized to Fc1 to serve as reference value.

To determine the affinity of each antibody, EP-HBS buffer (10 mM Hepes, 150 mM Sodium Chloride, 3 mM EDTA, 0.005% Polysorbate 20) at concentrations of 100 nM, 50 nM, 25 nM, 12.5 nM and 6.25 nM (GE Healthcare Bio-sciences AB , Sweden) to obtain a dissociation constant (K _off ) and a binding constant (K _on ) by injecting a flow rate at 30 ul / min, and affinity (K _D ) was derived from these. 10 mM Glycine-HCl (pH2.1) was injected at 30 ul / min flow rate for regeneration. In order to perform competitive epitope SPR, Cetuximab-Fab was injected at 400 nM 30ul / min for 120 seconds, and then EG L2 to L6 were injected again at a concentration of 50nm to 200nM to confirm the epitope difference with Cetuximan.

Example 2. Characteristics of Antibody Libraries

2.1 Panning Combination for EGFR Specific Phage Antibody Increase from HuDVFab-8L Human Fab Antibody Library

Pahge rescue using EX-12 helper phage was performed through human combinatorial Fab antibody library (HuDVFab-8L), through which phages bound to human Fab antibodies specific for EGFR were extracted. HuDVFab-8L used is Human naive heavy chain sublibrary HuNH-D2 (4.5 x 10 ⁹ in size) and human naive kappa light containing unidentified antigen binding capacity. chains) (HuL1 to HuL8), which consists of a sublibrary named HuDVFab-L1 to L8 (Hur et al., 2010). Initial panning was performed via the BRASIL technique using A431 as a positively expressing positive cell line in EGFR naïve form. U937 cell lines were also used negatively to remove phages that had nonspecific binding.

Four cell pannings were repeated for amplification of phage antibodies bound to EGFR expressed on the surface of A431 cells. The yield of phage derived after each round of panning was confirmed that the phage antibody binding to A431 was amplified by about 100 to 10,000 times (Table 1).

HuDVFab-8L Fab lib One ^st round 2 ^nd round 3 ^rd round 4 ^th round HuDVFab-L1 6.5ｘ10 ^-5 1.4ｘ10 ^-3 6ｘ10 ^-3 5ｘ10 ^-2 HuDVFab-L2 9ｘ10 ^-5 2ｘ10 ^-3 2ｘ10 ^-2 1ｘ10 ^-One HuDVFab-L3 7.2ｘ10 ^-5 1ｘ10 ^-3 1ｘ10 ^-2 4ｘ10 ^-2 HuDVFab-L4 7.1ｘ10 ^-5 1.6ｘ10 ^-3 1ｘ10 ^-2 2ｘ10 ^-2 HuDVFab-L5 7ｘ10 ^-5 8ｘ10 ^-6 4ｘ10 ^-3 1ｘ10 ^-2 HuDVFab-L6 1.4ｘ10 ^-4 1.1ｘ10 ^-3 1ｘ10 ^-2 7ｘ10 ^-2 HuDVFab-L7 8.5ｘ10 ^-5 1.3ｘ10 ^-3 6.6ｘ10 ^-4 3.7ｘ10 ^-3 HuDVFab-L8 4ｘ10 ^-5 9.4ｘ10 ^-4 2ｘ10 ^-2 1ｘ10 ^-One percent yield of output phage was determined as [output phage titer (cfu) / input phage titer (cfu)] ｘ 100.

However, since A431 cells contain not only EGFR but also numerous molecules expressed on the cell membrane, phage antibodies derived from cell panning are not very specific for EGFR. Therefore, in order to derive antibody-phage specific for EGFR, the recombinant EGFR-Fc protein was coated on an immuno tube and subjected to biopanning twice (Table 2).

HuDVFab-8L Fab lib One ^st round 2 ^nd round EGFR BSA Enrichment ^b EGFR BSA Enrichment HuDVFab-L1 2.4ｘ10 ^-3 8.5ｘ10 ^-4 2.8 3.5ｘ10 ^-4 7.5ｘ10 ^-5 4.7 HuDVFab-L2 1.1ｘ10 ^-One 2.5ｘ10 ^-4 440 ND ^c ND ND HuDVFab-L3 1.2ｘ10 ^-3 1ｘ10 ^-4 12 3ｘ10 ^-4 2ｘ10 ^-5 15 HuDVFab-L4 2.2ｘ10 ^-3 5ｘ10 ^-5 44 ND ND ND HuDVFab-L5 3ｘ10 ^-2 5ｘ10 ^-5 600 ND ND ND HuDVFab-L6 1.2ｘ10 ^-3 2.5ｘ10 ^-4 4.8 2.5ｘ10 ^-3 1.5ｘ10 ^-5 166.7 HuDVFab-L7 5ｘ10 ^-4 1ｘ10 ^-3 0.5 ND ND ND HuDVFab-L8 7.5ｘ10 ^-3 5ｘ10 ^-5 150 ND ND ND ^a percentage yield of output phage was determined as [output phage titer (cfu) / input phage titer (cfu)] ｘ 100.
^b Enrichment factor was calculated as [output phage titer (cfu) obtained from EGFR / output phage titer (cfu) obtained from BSA]. ^c Not done.

The yield of phage derived after one biopanning showed that the increase of EGFR-specific phage-antibodies was increased in HuDVFab-L2, HuDVFab-L4, HuDVFab-L5, and HuDVFab-L8 sublibrary. Could.

No noticeable increase was seen in the HuDVFab-L1, HuDVFab-L3, or HuDVFab-L6 sub-libraries, and in HuDVFab-L7 there was no increase in phage-antibody specific to EGFR. In the subsequent second panning, only the HuDVFab-L1, HuDVFab-L3, and HuDVFab-L6 sub-libraries were performed, but no significant increase in EGFR specific phage-antibody was observed in HuDVFab-L3 and HuDVFab-L6.

2.2 EGFR specific human Fab clone

To identify monoclonal levels of EGFR specific human Fab clones, 24 E. coli clones were selected from five sub-libraries of HuDVFab-L2, HuDVFab-L3, HuDVFab-L4, HuDVFab-L5 and HuDVFab-L6. Water-soluble Fabs were obtained from the supernatants obtained by culturing E. coli TG1, and subjected to monoclonal ELISA to screen for E. coli producing Fabs specific for EGFR and E with double positive binding signals. The V _H gene of the .coli strain was subjected to DNA sequencing (data not attached).

DNA sequencing confirmed the selection of E. coli containing five different genes, which were named EGL2, EGL3, EGL4, EGL5 and EGL6, respectively. In order to confirm the antigen-antibody specificity of these Fab clones, ELISA was performed on 6 proteins including EGFR-Fc, sEGFR, Her2-Fc, HGFR, BSA, and MBP-IL-15 (FIG. 1). Cetuximab was added as a positive control antibody.

As a result, as shown in FIG. 1, in all five clones, the expressed water-soluble Fab protein had specific binding ability to EGFR-Fc and sEGFR antigens, but did not bind to the other four antigen proteins. This shows that Fab clone has specific binding capacity to EGFR.

In addition, the binding capacity of Fab clones was measured by flow cytometry analysis. The antigenic protein used in the above experiment is a recombinant protein, and if it is artificially attached to the plastic surface, abnormal structural changes may occur in the intrinsic protein structure, which may cause a problem in measuring the binding force. A431 cells and DU145 cells were used to determine whether Fab clones bind to the unique EGFR distributed in the cell membrane. Cetuximab was used as a positive control antibody, and LP4, an antibody specific for PDC-E2, was used as a negative control antibody.

As a result, as shown in FIG. 2, the water-soluble Fab antibodies obtained from Fab clones had a stronger effective fluorescence intensity (Mean) than the goat anti-human kappa FITC conjugated used as secondary antibodies in A431 and DU145 as in Cetuximab. fluorescent intensity (MFI). No significant increase in MFI was seen when the anti-EGFR Fab antibody was reacted with HepG2, an EGFR negative cell line. This showed that the five EGFR Fab clones still retain specific binding to EGFR, which occurs naturally in cells.

2.3 Internalization Function of Fab Antibodies

Based on the above results, immunohistochemical staining was performed to confirm whether five Fab clones can exert internalization function into cells when treated with EGFR specific cells. Five purified Fab antibodies were incubated at 10 ug / ml in A431 cells and NIH3T3 cells for 3 hours at 5% CO ₂ , 37 ° C, and then stripped with stripping buffers to remove bound antibodies that remained on the cell surface without internalization. buffer) (50 mM glycine (pH2.8), 500 mM NaCl).

As a result of observing cells treated with Fab antibody using confocal microscopy, as shown in FIG. 3, it was confirmed that internalization occurred in A431 cells treated with Fab of EG L2, EG L3 and EG L4, but EG L5 and EG Specific internalization function could not be confirmed in A431 cells treated with L6 Fab. In addition, there was no change in NIH3T3 cells, EGFR negative cells.

2.4 Binding Specificity and Function of Anti-EGFR Fab Antibodies

In contrast to the in vivo experiment of the five clones selected through the panning it was confirmed that the binding to murine (EGFR). Recombinant murine EGFR was coated at 5 ug / ml by the same method as previously performed ELISA and reacted with EG L2, EG L3, EG L4, EG L5, and EG L6 Fab.

As shown in FIG. 4, specifically, EG L3 showed high binding to rmEGFR with other antibodies. EG L2 showed similar binding to Cetuximab or Panitumumab at rmEGFR, and EG L4, EG L5 and EGL6 showed very little or no binding signal.

From these inferences, it could be assumed that EG L3 will have different epitope binding sites than Cetuximab or Panitumumab.

EGFR combined with the EGF ligand forms high levels of dimers and then initiates phosphorylation at the C-terminus of tyrosine residues, resulting in immortalization of cancer cells. Accordingly, in order to confirm whether the clones could inhibit the propagation of cancer to cancer cells, a phosphotyrosine inhibition assay was performed.

As a result of treatment of 20nM EGF alone or with Fab antibody in A431 cells, it was confirmed that tyrosine phosphorylation was inhibited to a level similar to that of the positive control Cetuximab-Fab than when EGF alone was treated. .

In addition, surface plasmon resonance (SPR) was analyzed using Biacore X to determine the binding affinity of EG L2, EG L3, EG L4, EG L5 and EG L6 Fab antibodies.

After immobilizing the EGFR-Fc antigen on the CM5 sensor chip, the purified Fab antibodies were processed using CNBR-activated sepharose. The dissociation constants (KD), the binding affinity of EG L2, EG L3, EG L4, EG L5 and EG L6 Fab antibodies, were determined to be 54.3 nM, 40.4 nM, 3.92 nM, 178 nM and 282 nM, respectively. They were found to be close to or below the KD value of the commercially available Fab forms of Cetuximab and Panitumumab at 5.89 nM and 353 pM, respectively, when measuring SPR (FIG. 6 and Table 3).

Ka (M ^-1 S ^-1 )
(Association) Kd (S ^-1 )
(Dissociation) KD
(Affinity = Ka / Kd ) Chi2 values
(Confidence = <10) Cetuximab-Fab 3.33 x 10 ⁵ 1.96 x 10 ^-6 5.89 x 10 ^-9 4.15 Panitumumab-fab 4.55 x 10 ⁵ 1.61 x 10 ^-6 3.53 x ^{10 -10} 0.4 EG L2 1.19 x 10 ⁵ 6.44 x 10 ^-3 5.43 x 10 ^-8 0.477 EG L3 2.2 x 10 ⁵ 8.89 x 10 ^-3 4.04 x 10 ^-8 0.486 EG L4 3.04 x 10 ⁵ 1.19 x 10 ^-3 3.92 x 10 ^-9 4.15 EG L5 5.09 x 10 ⁴ 9.06 x 10 ^-3 1.78 x 10 ^-7 0.565 EG L6 2.92 x 10 ⁴ 8.24 x 10 ^-3 5.89 x 10 ^-7 0.851

To confirm whether the five EG Fab antibodies have different epitope binding regions from Cetuximab, a competitive SPR assay was performed. Cetuximab-Fab was allowed to bind.

with Cetuximab
(400nM) ① without Cetuximab
(400nM) ② % of inhibition
④ = 100 -③ EG L4 90.65 109 16.8 EG L3 43 53.5 19.6 EG L5 10.48 15 30.1 EG L6 10 22 54.5 EG L2 11.6 27.8 58.3 *% of binding ③ = ① / ②x100

As a result, as shown in Table 4 and Figure 7, the change in the RU did not occur even if the treatment at a concentration higher than about 400nM level. In addition, EG L2, EG L3, EG L4, EG L5, and EG L6 Fab were treated with 400 nM after 400 nM Cetuximab was treated. In the case of EG L3 and EG L4, even if Cetuximab was treated, EG L3 and EG L4 alone It was confirmed to recover to the RU value level when treated. It was determined that EG L3 and EG L4 have different epitopes from Cetuximab.

<110> IG Therapy <120> Anti-EGFR of cancer cell antibodies and uses <130> IPDB45032 <160> 40 <170> Kopatentin 2.0 <210> 1 <211> 11 <212> PRT <213> Homo sapiens <400> 1 Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn 1 5 10 <210> 2 <211> 12 <212> PRT <213> Homo sapiens <400> 2 Arg Ala Ser Glu Thr Val Ser Ser Arg Gln Leu Ala 1 5 10 <210> 3 <211> 11 <212> PRT <213> Homo sapiens <400> 3 Arg Ala Ser Gln Asn Ile Gly Ser Trp Leu Ala 1 5 10 <210> 4 <211> 11 <212> PRT <213> Homo sapiens <400> 4 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala 1 5 10 <210> 5 <211> 11 <212> PRT <213> Homo sapiens <400> 5 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 6 <211> 7 <212> PRT <213> Homo sapiens <400> 6 Gly Ala Ser Arg Leu Glu Ser 1 5 <210> 7 <211> 7 <212> PRT <213> Homo sapiens <400> 7 Gly Ala Ser Ser Ala Thr 1 5 <210> 8 <211> 7 <212> PRT <213> Homo sapiens <400> 8 Arg Ala Ser Asn Leu Arg Ser 1 5 <210> 9 <211> 7 <212> PRT <213> Homo sapiens <400> 9 Gly Ala Ser Thr Arg Ala Thr 1 5 <210> 10 <211> 7 <212> PRT <213> Homo sapiens <400> 10 Tyr Ala Ala Ser Ser Leu Gln 1 5 <210> 11 <211> 9 <212> PRT <213> Homo sapiens <400> 11 Gln Gln Ser Asp Ser Val Pro Val Thr 1 5 <210> 12 <211> 9 <212> PRT <213> Homo sapiens <400> 12 Gln Gln Tyr Gly Ser Ser Pro Arg Thr 1 5 <210> 13 <211> 9 <212> PRT <213> Homo sapiens <400> 13 Gln Gln Ala Thr Ile Phe Pro Leu Thr 1 5 <210> 14 <211> 10 <212> PRT <213> Homo sapiens <400> 14 Gln Gln Tyr Asn Asn Trp Pro Pro Tyr Thr 1 5 10 <210> 15 <211> 10 <212> PRT <213> Homo sapiens <400> 15 Gln Gln Ser Tyr Ser Thr Pro Pro Tyr Thr 1 5 10 <210> 16 <211> 5 <212> PRT <213> Homo sapiens <400> 16 Asn Tyr Asn Ile Asn 1 5 <210> 17 <211> 5 <212> PRT <213> Homo sapiens <400> 17 Ser Tyr Trp Met Thr 1 5 <210> 18 <211> 5 <212> PRT <213> Homo sapiens <400> 18 Asp Tyr Ala Met His 1 5 <210> 19 <211> 5 <212> PRT <213> Homo sapiens <400> 19 Asn Tyr Gly Ile Ser 1 5 <210> 20 <211> 5 <212> PRT <213> Homo sapiens <400> 20 Ser Tyr Ala Val Asn 1 5 <210> 21 <211> 17 <212> PRT <213> Homo sapiens <400> 21 Trp Met Asn Pro Tyr Thr Gly Asp Thr Gly Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 22 <211> 17 <212> PRT <213> Homo sapiens <400> 22 Asn Ile Arg Gln Asp Gly Asn Glu Lys Tyr Tyr Leu Asp Ser Val Lys 1 5 10 15 Gly <210> 23 <211> 17 <212> PRT <213> Homo sapiens <400> 23 Gly Ile Ser Trp Asn Gly Gly Ser Val Val Tyr Ala Asp Ser Val Arg 1 5 10 15 Gly <210> 24 <211> 17 <212> PRT <213> Homo sapiens <400> 24 Trp Ile Arg Pro Tyr Asn Gly Asn Thr Asp Tyr Ala Gln Lys Val Gln 1 5 10 15 Gly <210> 25 <211> 17 <212> PRT <213> Homo sapiens <400> 25 Gly Ile Ile Pro Val Phe Ala Thr Pro Asn Tyr Ala Gln Asn Phe Gln 1 5 10 15 Gly <210> 26 <211> 10 <212> PRT <213> Homo sapiens <400> 26 Arg Trp Asp Asn Phe Gly Ala Phe Asp Ile 1 5 10 <210> 27 <211> 14 <212> PRT <213> Homo sapiens <400> 27 Glu Tyr Glu Asn Tyr Asp Ile Leu Thr Thr Tyr Leu Asp Tyr 1 5 10 <210> 28 <211> 9 <212> PRT <213> Homo sapiens <400> 28 Asp Tyr Gly Tyr Tyr Gly Met Asp Val 1 5 <210> 29 <211> 10 <212> PRT <213> Homo sapiens <400> 29 Tyr Asp Tyr Ala Thr Gly Trp Phe Asp Pro 1 5 10 <210> 30 <211> 16 <212> PRT <213> Homo sapiens <400> 30 Asp Arg Tyr Phe Asp Trp Leu Leu Gly Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 31 <211> 108 <212> PRT <213> Homo sapiens <400> 31 Glu Leu Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asp Ser Val Pro Val 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg 100 105 <210> 32 <211> 109 <212> PRT <213> Homo sapiens <400> 32 Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Thr Val Ser Ser Arg 20 25 30 Gln Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Ser Ala Val Phe Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <210> 33 <211> 108 <212> PRT <213> Homo sapiens <400> 33 Asp Ile Val Met Thr Gln Ser Ser Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Gly Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Arg Ala Ser Asn Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Ala Thr Ile Phe Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Arg Val Asp Ile Lys Arg 100 105 <210> 34 <211> 108 <212> PRT <213> Homo sapiens <400> 34 Asp Ile Gln Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Val Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 35 40 45 Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu 65 70 75 80 Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Arg Val Glu Ile Lys Arg 100 105 <210> 35 <211> 109 <212> PRT <213> Homo sapiens <400> 35 Asp Ile Val Met Thr Gln Ser Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ser Ser Leu Gln Ser Gly Val Ser Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <210> 36 <211> 119 <212> PRT <213> Homo sapiens <400> 36 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ile Asn Tyr 20 25 30 Asn Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Tyr Thr Gly Asp Thr Gly Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Arg Trp Asp Asn Phe Gly Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val Thr Val Ser Ser 115 <210> 37 <211> 123 <212> PRT <213> Homo sapiens <400> 37 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Arg Gln Asp Gly Asn Glu Lys Tyr Tyr Leu Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Tyr Glu Asn Tyr Asp Ile Leu Thr Thr Tyr Leu Asp Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 38 <211> 118 <212> PRT <213> Homo sapiens <400> 38 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Gly Gly Ser Val Val Tyr Ala Asp Ser Val 50 55 60 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser 115 <210> 39 <211> 119 <212> PRT <213> Homo sapiens <400> 39 Gln Val Gln Leu Leu Gln Ser Gly Ala Glu Val Glu Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Ser Leu Ser Asn Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu 35 40 45 Gly Trp Ile Arg Pro Tyr Asn Gly Asn Thr Asp Tyr Ala Gln Lys Val 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Asn Ile Ala Tyr 65 70 75 80 Met Glu Leu Arg Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Tyr Asp Tyr Ala Thr Gly Trp Phe Asp Pro Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 40 <211> 125 <212> PRT <213> Homo sapiens <400> 40 Gln Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Val Phe Ala Thr Pro Asn Tyr Ala Gln Asn Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Asp Leu Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Tyr Phe Asp Trp Leu Leu Gly Tyr Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125

Claims

By the Kabat numbering system,
L (24) -L (25) -L (26) -L (27) -L (27A) -L (28) -L (29) -L (30) -L (31) -L (32)- Light chain CDR1 region represented by L (33) -L (34);
Light chain CDR2 region represented by L (50) -L (51) -L (52) -L (53) -L (54) -L (55);
L (89) -L (90) -L (91) -L (92) -L (93) -L (94) -L (95) -L (95A) -L (96) -L (97) Indicated light chain CDR3 regions;
A heavy chain CDR1 region represented by H (31) -H (32) -H (33) -H (34) -H (35);
H (50) -H (51) -H (52) -H (52A) -H (53) -H (54) -H (55) -H (56) -H (57) -H (58)- A heavy chain CDR2 region represented by H (59) -H (60) -H (61) -H (62) -H (63) -H (64) -H (65); And
Heavy chain CDR3 region represented by H (95) -H (96) -H (97) -H (98) -H (99) -H (100) -H (100A) -H (101) -H (102) Including,
L 24 is R;
L 25 is A;
L 26 is S;
L 27 is Q or E;
L 27A is T;
L 28 may be any one of S, V or N;
L (29) is I or S
L 30 is any one of S, G or V;
L 31 is R or S;
L 32 is any one of Y, Q, W or S;
L 33 is L or N;
L 34 is any one of N, A or L;
L 50 is G or A;
L 51 is A;
L 52 is S;
L 53 is any one of R, S, N or T;
L 54 is L or R;
L 55 may be any one of E, A, R or Q;
L 89 is Q;
L 90 is Q;
L 91 is any one of S, Y or A;
L 92 is any one of D, G, T, N or Y;
L 93 is any one of S, I or N;
L 94 is any one of V, S, F, W or T;
L 95 is P;
L 95A is P;
L 96 is any one of V, R, L or Y;
L 97 is T;
H (31) is any one of N, D or S;
H (32) is Y
H 33 is any one of N, W, A or G;
H 34 is any one of I, M or V;
H 35 is any one of N, T, H or S;
H 50 is any of W, N or G;
H 51 is M or I;
H 52 is any one of N, R, S or I;
H 52A is any one of P, Q or W;
H 53 is any one of Y, D, N or V;
H 54 is any one of T, G, N or F;
H 55 is any one of G, N or A;
H 56 is any one of D, E, S, N or T;
H 57 is any one of T, K, V or P;
H 58 is any one of G, Y, V, D or N;
H 59 is Y;
H 60 is A or L;
H 61 is Q or D;
H 62 is any one of K, S or N;
H 63 is F or V;
H 64 is any of Q, K or R;
H 65 is G;
H 95 is any one of R, E, D or Y;
H 96 is any one of W, Y, D or R;
H (97) is any one of D, E, G or Y;
H 98 is any one of N, Y, A or F;
H (99) is any one of F, Y, T or D;
H (100) is any one of G, D or W;
H (100A) is any one of A, I, M, W or L;
H 101 is D; And
H (102) is any one of I, Y, V or P, the antibody that specifically binds to cancer cells.

The method of claim 1,
The light chain CDR 1 is any one of SEQ ID NOs: 1 to 5;
The light chain CDR 2 is any one of SEQ ID NOs: 6 to 10;
The light chain CDR 3 is any one of SEQ ID NOs: 11 to 15;
The heavy chain CDR 1 is any one of SEQ ID NOs: 16 to 20;
The heavy chain CDR 2 is any one of SEQ ID NOs: 21 to 25; And
The heavy chain CDR 3 is an antibody that specifically binds to cancer cells, characterized in that any one of SEQ ID NOs: 26 to 30.

The method of claim 1,
The antibody specifically binds to cancer cells, characterized in that it comprises the amino acid sequence of any one group selected from the following group:
The first group includes a light chain CDR 1 region represented by SEQ ID NO: 1, a light chain CDR 2 region represented by SEQ ID NO: 6, a light chain CDR 3 region represented by SEQ ID NO: 11, a heavy chain CDR 1 region represented by SEQ ID NO: 16, SEQ ID NO: A heavy chain CDR 2 region represented by 21 and a heavy chain CDR 3 region represented by SEQ ID NO: 26;
The second group includes the light chain CDR 1 region represented by SEQ ID NO: 2, the light chain CDR 2 region represented by SEQ ID NO: 7, the light chain CDR 3 region represented by SEQ ID NO: 12, the heavy chain CDR 1 region represented by SEQ ID NO: 17, SEQ ID NO: A heavy chain CDR 2 region represented by 22 and a heavy chain CDR 3 region represented by SEQ ID NO: 27;
The third group includes a light chain CDR 1 region represented by SEQ ID NO: 3, a light chain CDR 2 region represented by SEQ ID NO: 8, a light chain CDR 3 region represented by SEQ ID NO: 13, a heavy chain CDR 1 region represented by SEQ ID NO: 18, SEQ ID NO: A heavy chain CDR 2 region represented by 23 and a heavy chain CDR 3 region represented by SEQ ID NO: 28;
The fourth group includes the light chain CDR 1 region represented by SEQ ID NO: 4, the light chain CDR 2 region represented by SEQ ID NO: 9, the light chain CDR 3 region represented by SEQ ID NO: 14, the heavy chain CDR 1 region represented by SEQ ID NO: 19, SEQ ID NO: A heavy chain CDR 2 region represented by 24 and a heavy chain CDR 3 region represented by SEQ ID NO: 29; And
The fifth group includes the light chain CDR 1 region represented by SEQ ID NO: 5, the light chain CDR 2 region represented by SEQ ID NO: 10, the light chain CDR 3 region represented by SEQ ID NO: 15, the heavy chain CDR 1 region represented by SEQ ID NO: 20, SEQ ID NO: A heavy chain CDR 2 region represented by 25 and a heavy chain CDR 3 region represented by SEQ ID NO.

The method of claim 3, wherein
The antibody specifically binds to cancer cells, characterized in that it comprises an amino acid sequence of the second group or the third group.

The method of claim 1,
The antibody is any one of SEQ ID NOs: 31 to 35; And an amino acid sequence of any one of SEQ ID NOs: 36 to 40.

The method of claim 1,
The antibody specifically binds to cancer cells, characterized in that it comprises the amino acid sequence of any one group selected from the following group:
The sixth group comprises SEQ ID NO: 31 and SEQ ID NO: 36;
The seventh group comprises SEQ ID NO: 32 and SEQ ID NO: 37;
The eighth group comprises SEQ ID NO: 33 and SEQ ID NO: 38;
The ninth group comprises SEQ ID NO: 34 and SEQ ID NO: 39; And
The tenth group is SEQ ID NO: 35 and SEQ ID NO: 40.

The method according to claim 6,
The antibody specifically binds to cancer cells, characterized in that it comprises amino acid sequences of the seventh or eighth group.

The method of claim 1,
The antibody specifically binds to cancer cells, characterized in that it specifically binds to EGFR (Epidermal growth factor receptor) of cancer cells.

By the Kabat numbering system,
L (24) -L (25) -L (26) -L (27) -L (27A) -L (28) -L (29) -L (30) -L (31) -L (32)- A first area represented by L 33-L 34;
A second area represented by L (50) -L (51) -L (52) -L (53) -L (54) -L (55);
L (89) -L (90) -L (91) -L (92) -L (93) -L (94) -L (95) -L (95A) -L (96) -L (97) A third area displayed;
A fourth region represented by H (31) -H (32) -H (33) -H (34) -H (35);
H (50) -H (51) -H (52) -H (52A) -H (53) -H (54) -H (55) -H (56) -H (57) -H (58)- A fifth region represented by H (59) -H (60) -H (61) -H (62) -H (63) -H (64) -H (65); And
Sixth region represented by H (95) -H (96) -H (97) -H (98) -H (99) -H (100) -H (100A) -H (101) -H (102) Including,
L 24 is R;
L 25 is A;
L 26 is S;
L 27 is Q or E;
L 27A is T;
L 28 may be any one of S, V or N;
L (29) is I or S
L 30 is any one of S, G or V;
L 31 is R or S;
L 32 is any one of Y, Q, W or S;
L 33 is L or N;
L 34 is any one of N, A or L;
L 50 is G or A;
L 51 is A;
L 52 is S;
L 53 is any one of R, S, N or T;
L 54 is L or R;
L 55 may be any one of E, A, R or Q;
L 89 is Q;
L 90 is Q;
L 91 is any one of S, Y or A;
L 92 is any one of D, G, T, N or Y;
L 93 is any one of S, I or N;
L 94 is any one of V, S, F, W or T;
L 95 is P;
L 95A is P;
L 96 is any one of V, R, L or Y;
L 97 is T;
H (31) is any one of N, D or S;
H (32) is Y
H 33 is any one of N, W, A or G;
H 34 is any one of I, M or V;
H 35 is any one of N, T, H or S;
H 50 is any of W, N or G;
H 51 is M or I;
H 52 is any one of N, R, S or I;
H 52A is any one of P, Q or W;
H 53 is any one of Y, D, N or V;
H 54 is any one of T, G, N or F;
H 55 is any one of G, N or A;
H 56 is any one of D, E, S, N or T;
H 57 is any one of T, K, V or P;
H 58 is any one of G, Y, V, D or N;
H 59 is Y;
H 60 is A or L;
H 61 is Q or D;
H 62 is any one of K, S or N;
H 63 is F or V;
H 64 is any of Q, K or R;
H 65 is G;
H 95 is any one of R, E, D or Y;
H 96 is any one of W, Y, D or R;
H (97) is any one of D, E, G or Y;
H 98 is any one of N, Y, A or F;
H (99) is any one of F, Y, T or D;
H (100) is any one of G, D or W;
H (100A) is any one of A, I, M, W or L;
H 101 is D; And
H 102 is a binding molecule of any one of I, Y, V or P.

The method of claim 9,
The first region is any one of SEQ ID NOs: 1 to 5;
The second region is any one of SEQ ID NOs: 6-10;
The third region is any one of SEQ ID NOs: 11 to 15;
The fourth region is any one of SEQ ID NOs: 16-20;
The fifth region is any one of SEQ ID NOs: 21 to 25; And
The sixth region is a binding molecule, characterized in that any one of SEQ ID NOs: 26 to 30.

The method of claim 9,
The antibody comprises a binding molecule comprising an amino acid sequence of any one group selected from the following groups:
The first group includes a first region represented by SEQ ID NO: 1, a second region represented by SEQ ID NO: 6, a third region represented by SEQ ID NO: 11, a fourth region represented by SEQ ID NO: 16, and represented by SEQ ID NO: 21. A fifth region and a sixth region represented by SEQ ID NO: 26;
The second group includes a first region represented by SEQ ID NO: 2, a second region represented by SEQ ID NO: 7, a third region represented by SEQ ID NO: 12, a fourth region represented by SEQ ID NO: 17, and represented by SEQ ID NO: 22. A sixth region represented by a fifth region and SEQ ID NO: 27;
The third group includes a first region represented by SEQ ID NO: 3, a second region represented by SEQ ID NO: 8, a third region represented by SEQ ID NO: 13, a fourth region represented by SEQ ID NO: 18, and represented by SEQ ID NO: 23. A sixth region represented by a fifth region and SEQ ID NO: 28;
The fourth group includes a first region represented by SEQ ID NO: 4, a second region represented by SEQ ID NO: 9, a third region represented by SEQ ID NO: 14, a fourth region represented by SEQ ID NO: 19, and represented by SEQ ID NO: 24. A fifth region and a sixth region represented by SEQ ID NO: 29; And
The fifth group includes a first region represented by SEQ ID NO: 5, a second region represented by SEQ ID NO: 10, a third region represented by SEQ ID NO: 15, a fourth region represented by SEQ ID NO: 20, and represented by SEQ ID NO: 25. A sixth region represented by a fifth region and SEQ ID NO.

12. The method of claim 11,
The binding molecule of claim 2, wherein the binding molecule comprises a second or third group of amino acid sequences.

The method of claim 9,
The binding molecule is a binding molecule, characterized in that any one of a single-chain variable fragment (scFv), disulfide-stabilized Fv antibody fragment (DsFv) or a bispecific antibody (bispecific antibody).

An antibody-drug conjugate (ADC) in which a drug is bound to the antibody of any one of claims 1 to 8.

A vector comprising a gene encoding the antibody of any one of claims 1 to 8.

A cell line comprising the vector of claim 15.

17. The method of claim 16,
The cell line is a cell line, characterized in that any one of A. TG1, ER2537 or Electro ten-blue.

A method of producing an antibody comprising transfecting a vector of claim 15 into a cell line.

19. The method of claim 18,
The cell line is A. TG1, ER2537 or Electro ten-blue any one of the methods for producing an antibody.

19. The method of claim 18,
The antibody is a method of producing an antibody, characterized in that specifically binding to cancer cells.

19. The method of claim 18,
The antibody is a method for producing an antibody, characterized in that specifically binding to EGFR of cancer cells.

A pharmaceutical composition for treating cancer, comprising the antibody of any one of claims 1 to 8 or the antibody-drug conjugate (ADC) of claim 14.

23. The method of claim 22,
The composition is a pharmaceutical composition for treating cancer, characterized in that the oral formulation, external preparation, suppository or sterile injectable solution.

A cancer diagnostic kit comprising the antibody of any one of claims 1 to 8.

A method of providing information on the presence of EGFR protein in cancer cells comprising the step of reacting the antibody of any one of claims 1 to 8 with a desired sample.